Mosende C, Gutierrez M, Caparros B, Rosen G
Cancer. 1977 Dec;40(6):2779-86. doi: 10.1002/1097-0142(197712)40:6<2779::aid-cncr2820400604>3.0.co;2-e.
Thirteen patients with osteogenic sarcoma were treated with multiple drug chemotherapy consisting of bleomycin, cyclophosphamide and dactinomycin. The dosage schedule used was: bleomycin 12 mg/m2/day, cyclophosphamide 600 mg/m2/day, and dactinomycin 450 microgram/m2/day. All drugs were given intravenously for two consecutive days. Treatment was repeated every 2 weeks. Toxicity included severe nausea and vomiting (managed with antiemetics and intravenous hydration) and manifestations of bone marrow depression. Of 13 patients, eight were previously treated with high dose methotrexate with citrovorum factor rescue, cyclophosphamide and Adriamycin. Of these eight, three patients had objective evidence of tumor regression (37.5%). Five of five previously untreated patients had objective evidence of tumor regression. The overall response rate in osteogenic sarcoma patients to BCD was 61.5%. The combination of BCD appears to be more active against osteogenic sarcoma than cyclophosphamide alone or Adriamycin alone. The relative safety with which BCD can be administered makes this combination a valuable adjunct to high dose methotrexate with citrovorum factor rescue and Adriamycin in the treatment of osteogenic sarcoma.
13例骨肉瘤患者接受了由博来霉素、环磷酰胺和放线菌素组成的联合化疗。所用的给药方案为：博来霉素12毫克/平方米/天，环磷酰胺600毫克/平方米/天，放线菌素450微克/平方米/天。所有药物均连续静脉注射两天。每2周重复一次治疗。毒性反应包括严重恶心和呕吐（用止吐药和静脉补液处理）以及骨髓抑制表现。13例患者中，8例曾接受过用甲酰四氢叶酸解救的大剂量甲氨蝶呤、环磷酰胺和阿霉素治疗。在这8例患者中，3例有肿瘤消退的客观证据（37.5%）。5例未接受过治疗的患者中有5例有肿瘤消退的客观证据。骨肉瘤患者对BCD方案的总体缓解率为61.5%。BCD联合方案似乎比单独使用环磷酰胺或单独使用阿霉素对骨肉瘤更有效。BCD方案相对安全的给药方式使其成为大剂量甲氨蝶呤加甲酰四氢叶酸解救及阿霉素治疗骨肉瘤的一种有价值的辅助治疗方法。
